Internal Medicine, Hematology & Oncology · Riverside, CA
NPI
1508185406
Since 2010
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
4500 Brockton Ave Ste 107
Riverside, CA, 92501
Phone (951) 276-2760
Groups this clinician bills Medicare through
Medicare paid, 2024
$447K
31,302 services
Medicare patients, 2024
161
Average age 72
Drug cost, 2024
$3.7M
1,481 prescriptions
Company payments, 2025
$4,607
From 50 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Laxmi S Iyer was code J1100 (injection, dexamethasone sodium phosphate, 1 mg), 808 times for 14 patients. In total Laxmi S Iyer billed 31,302 services in 72 codes, and Medicare paid $447K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-06-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 808 | 14 | $0.09 | $72.65 |
| 99214 Office E&M - Established | Office | 298 | 103 | $98.72 | $29K |
| 96413 Chemotherapy Administration | Office | 70 | 17 | $107.31 | $7,512 |
| 96127 Behavioral Health Services | Office | 70 | 62 | $3.83 | $268 |
| 96367 Intravenous Infusion, Hydration | Office | 69 | 18 | $23.59 | $1,627 |
| 99233 Hospital E&M - Subsequent | Facility | 68 | 34 | $94.35 | $6,416 |
| 96415 Chemotherapy Administration | Office | 53 | 13 | $22.86 | $1,212 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 51 | 13 | $0.61 | $31.28 |
| 96365 Intravenous Infusion, Hydration | Office | 33 | 17 | $46.81 | $1,545 |
| 99223 Hospital E&M - Initial | Facility | 29 | 29 | $137.35 | $3,983 |
| 99204 Office E&M - New | Office | 16 | 16 | $120.13 | $1,922 |
By year: 2022 $69K for 8,894 services; 2023 $207K for 22,653 services; 2024 $447K for 31,302 services.
Medicare prescription drug claims, 2024
In 2024, the drug Laxmi S Iyer prescribed most often to Medicare patients was Anastrozole, with 174 prescriptions and refills. In total Laxmi S Iyer wrote 1,481 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 174 | 378 | 60 | $3,216 |
| Diphenhydramine Hcl Generic | 66 | 67 | 20 | $98.84 |
| Dexamethasone Sodium Phosphate Generic | 58 | 59 | 19 | $155 |
| Letrozole Generic | 47 | 110 | 15 | $953 |
| Ondansetron Hcl Ondansetron Hcl/Pf | 41 | 42 | Under 11 | $57.59 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 38 | 38 | 18 | $763 |
| Trazimera Trastuzumab-Qyyp | 35 | 35 | Under 11 | $126K |
| Carboplatin Generic | 35 | 36 | Under 11 | $1,655 |
| Famotidine Famotidine/Pf | 35 | 36 | 12 | $45.93 |
| Prednisone Generic | 34 | 38 | 14 | $167 |
| Ruxience Rituximab-Pvvr | 27 | 27 | Under 11 | $143K |
| Imbruvica Ibrutinib | 26 | 26 | Under 11 | $434K |
| Oxaliplatin Generic | 25 | 25 | Under 11 | $1,239 |
| Fosaprepitant Dimeglumine Generic | 24 | 24 | Under 11 | $2,637 |
| Docetaxel Generic | 24 | 24 | Under 11 | $6,119 |
Brand drugs: 427 claims; generic drugs: 1,054 claims; opioid claims: 67.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Laxmi S Iyer $4,607 ($4,607 in general payments such as food, travel and fees) from 50 companies. The largest payer was Janssen Biotech, Inc. with $476.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 15 | $476 |
| Pfizer Inc. PFE | 18 | $388 |
| Novartis Pharmaceuticals Corporation NVS | 15 | $276 |
| Celgene Corporation BMY | 11 | $230 |
| Karyopharm Therapeutics Inc. KPTI | 20 | $229 |
| Merck Sharp & Dohme LLC MRK | 7 | $207 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $204 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 12 | $164 |
| Incyte Corporation INCY | 7 | $151 |
| Abbvie Inc. ABBV | 5 | $130 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.